Structured Therapeutic Dressing Maximizing Procoagulant Surface Area
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing wound dressings face challenges in effectively controlling hemorrhage due to limited surface area exposure of procoagulant agents, potential shedding of fillers, and inability to maintain agents at the wound site, especially in high-bleeding situations or irregularly shaped wounds.
Innovation Solution
A conformable structured therapeutic dressing with a high surface area of functional fillers, such as silica and chitosan, is developed, utilizing a minimal binder and small, porous particles to maximize the availability and retention of procoagulants like silica and chitosan, which work synergistically with other clotting initiators to enhance hemostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Area of stationary object
If a minimal amount of binder is used to hold functional fillers, then the surface area of procoagulant agents is maximized, but the structural integrity and retention of fillers at the wound site deteriorates
Solution Approach 1:
The patent uses a thin film or coating of binder material to encapsulate or adhere functional fillers, creating a flexible structure that maintains filler retention while preserving maximum surface area exposure. The thin film approach prevents filler shedding without significantly blocking active surfaces.
Solution Approach 2:
The patent creates a composite material system combining binder, functional fillers (procoagulant agents), and potentially other therapeutic agents in a structured arrangement. This composite structure optimizes the balance between filler retention through binder adhesion and surface area availability for hemostatic activity.
2Area of stationary object
If small, porous particles are used for functional fillers, then the surface area to volume ratio is maximized, but the mechanical strength and handling properties of the dressing deteriorates
Solution Approach 1:
The patent employs porous particles as functional fillers, which provide high surface area to volume ratios for enhanced procoagulant activity. The porous structure increases the effective surface area available for blood contact and clotting factor activation while maintaining manageable particle characteristics through controlled pore size and distribution.
Solution Approach 2:
The patent optimizes particle parameters including size, porosity, and surface characteristics to achieve the desired balance. By controlling particle diameter, pore size, and surface area, the dressing maximizes hemostatic efficacy while maintaining adequate mechanical properties for handling and application.
3Quantity of substance
If functional fillers are impregnated or coated onto fibers, then the therapeutic agent availability is improved, but excessive shedding of filler occurs
Solution Approach 1:
The patent extracts or removes excess binder material to prevent filler shedding, or alternatively, removes the binder entirely in favor of a filler matrix structure where fillers are held together by minimal binder or by inter-filler interactions, thereby eliminating the shedding problem while maintaining therapeutic agent availability.
Solution Approach 2:
The patent employs preliminary actions during fabrication such as controlled impregnation, suffusion, or coating processes that ensure thorough and uniform distribution of functional fillers within the fiber matrix before final processing. This preliminary integration prevents subsequent filler shedding during use while maximizing therapeutic agent availability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dressing achieves rapid and robust clot formation by maximizing the surface area of procoagulants, maintaining them at the wound site, and facilitating multiple clotting mechanisms, thereby effectively controlling bleeding and promoting hemostasis in various wound geometries.
Implementation Method 1
the articles have an unusually high percentage of functional fillers and very large surface areas. These properties, coupled with the selection of appropriate functional fillers, increase the efficacy of the disclosed articles
Implementation Method 2
A conformable structured therapeutic dressing with a high surface area of functional fillers, such as silica and chitosan, is developed, utilizing a minimal binder and small, porous particles to maximize the availability and retention of procoagulants like silica and chitosan, which work synergistically with other clotting initiators to enhance hemostasis
Data Source
AI summary
A conformable structured therapeutic dressing (120) has maximum available surface area (102) of a therapeutic agent (122) to stimulate therapeutic response in wounded tissue of a mammalian subject. In preferred embodiments, the therapeutic agent includes a procoagulant to quickly arrest bleeding and prevent life-threatening blood loss. The wound dressing exhibits a structured adsorbent (104) that maximizes available surface area of a functional filler (72). This is achieved with a minimal amount of binder (82) and small, porous particles of the functional filler. Minimizing the binder maximizes the amount of functional filler and reduces the chance that the binder will block access to the surface area of the functional filler. Porous particles have a large internal surface area. Structured adsorbents with higher surface areas, higher inter- and intra-fiber porosities, and low internal mass transfer resistances produce higher rates of mass transfer of an adsorbent onto the functional filler.